Puma Biotechnology Inc (NYSE:PBYI) : Traders are bullish on Puma Biotechnology Inc (NYSE:PBYI) as it has outperformed the S&P 500 by a wide margin of 2.74% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 13.96%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 15.42% in the last 1 week, and is up 4.4% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -67.10% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $111.22 and the one year low was seen on May 10, 2016. The 50-Day Moving Average price is $33.08 and the 200 Day Moving Average price is recorded at $39.76.
The stock has recorded a 20-day Moving Average of 11.64% and the 50-Day Moving Average is 12.21%.
Puma Biotechnology Inc (NYSE:PBYI): stock turned positive on Friday. Though the stock opened at $32.15, the bulls momentum made the stock top out at $35.16 level for the day. The stock recorded a low of $32.11 and closed the trading day at $34.88, in the green by 8.49%. The total traded volume for the day was 744,644. The stock had closed at $32.15 in the previous days trading.
In an insider trading activity, The officer (SR VP, CLINICAL RESEARCH & DEV), of Puma Biotechnology, Inc., Bryce Richard Paul had unloaded 3,000 shares at $110.03 per share in a transaction on July 6, 2015. The total value of transaction was $330,090. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.